Clinical Trials
6 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed